Johnson Investment Counsel Inc. Sells 1,845 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Johnson Investment Counsel Inc. reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 8.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,942 shares of the medical research company's stock after selling 1,845 shares during the quarter. Johnson Investment Counsel Inc.'s holdings in Charles River Laboratories International were worth $3,681,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Versant Capital Management Inc raised its holdings in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after acquiring an additional 150 shares during the period. Assetmark Inc. boosted its holdings in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after buying an additional 173 shares during the period. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Charles River Laboratories International in the 3rd quarter worth about $59,000. Finally, ORG Wealth Partners LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at approximately $56,000. 98.91% of the stock is owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Barclays reduced their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 18th. The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Morgan Stanley reduced their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 5th. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. Finally, Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price for the company in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $198.36.

Charles River Laboratories International Price Performance

NYSE:CRL traded up $4.34 during mid-day trading on Friday, hitting $171.27. 1,034,089 shares of the company's stock traded hands, compared to its average volume of 709,529. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The firm's 50 day simple moving average is $168.35 and its 200 day simple moving average is $185.07. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $274.77. The company has a market cap of $8.76 billion, a PE ratio of 1,141.78, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.46 earnings per share. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Birgit Girshick bought 1,514 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).